Monitor upcoming operating expense trends in 2026 filings to assess burn rate acceleration ahead of commercial launch. Track Early Access Program adoption and any future revenue recognition as leading indicators of commercial traction.
Price Chart
Executive Summary
Nautilus Biotechnology reported reduced operating expenses and net losses for Q4 and full-year 2025, with $156.1 million in cash as of year-end. The company expects operating expenses to rise 15-20% in 2026 and does not anticipate material revenue from its Early Access Program. The filing reflects continued R&D and commercial preparation for its Voyager platform ahead of a late-2026 launch.
Key Financial Metrics
Key Facts
- Operating expenses decreased 23% YoY to $15.4M in Q4 2025 and 18% to $66.8M for full-year 2025
- Net loss improved to $13.8M in Q4 2025 vs $17.6M in prior year; full-year net loss was $59.0M vs $70.8M
- Cash, cash equivalents, and investments totaled $156.1 million as of December 31, 2025
- No material revenue expected from Early Access Program in 2026
- Operating expenses expected to increase 15-20% in 2026 vs 2025
- Sufficient cash to fund operations through 2027
Financial Impact
Operating expenses down $14.6M annually, net loss reduced by $11.8M year-over-year
Risk Factors
- Significant increase in operating expenses in 2026 could accelerate cash burn
- No material revenue expected in 2026 despite commercial launch plans
- Company remains in development stage with unproven commercial viability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001808805-26-000004 |
| Document: naut-20260226.htm | 0001808805-26-000004 |
| Document: 0001808805-26-000004-index-headers.html | 0001808805-26-000004 |
| Document: 0001808805-26-000004-index.html | 0001808805-26-000004 |
| Document: 0001808805-26-000004.txt | 0001808805-26-000004 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Apr 28, 2026 22w ago | Press Release | $2.59 $1.77 | ▼ −31.66% | ▼ −35.65% | $1.86 (−28.38%) |
Apr 28, 2026 22w ago | 8-K | $2.59 $1.77 | ▼ −31.66% | ▼ −35.65% | $1.86 (−28.38%) |
Mar 18, 2026 28w ago | Press Release | $2.74 $2.29 | ▼ −16.61% | ▼ −28.13% | $1.86 (−32.30%) |
Feb 26, 2026 31w ago | 8-K | $2.42 $2.54 | ▲ +4.96% | ▼ −2.79% | $1.86 (−23.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access